Mablink Bioscience
Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
Lyon, Francewww.mablink.com ↗
Total raised
€35M
€35,000,000
Funding rounds
2
Investors
9
distinct backers
Active since
2021-04
latest 2022-10
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood36
base rate 44% for Series A
- ▼ Overdue vs cohort gap
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood14
base rate 12% (2+ rounds)
- ▲ €30M+ raised
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-17 | Series A | €31M | Crédit Agricole Création,Elaia Partners,Fondation Fournier-Majoie,Mérieux Equity Partners,Sham Innovation Santé,Simba Santé+2 more | View deal → |
| 2021-04-27 | Seed | €4.0M | Crédit Agricole Création,Elaia Partners,Fondation Fournier-Majoie,Pertinence Invest 2,Sham Innovation Santé,Simba Santé | View deal → |
Investors
9Related news
- Mablink Bioscience secures €31M to develop better treatment for cancer patientstechfundingnews.com · 2022-10
- finsmes.com
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software